Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys

Brain Research

Volumn 719, Issue 1-2, 1996, Pages 129-137

  Goulet, M ^a   Grondin, R ^b   Blanchet, P J ^b   Bedard P J ^b   Di Paolo, T ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b NONE

Author keywords

Dopamine receptor; Dyskinesia; Monkey; MPTP; Parkinson's disease; Tolerance

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DYSKINESIA; FEMALE; MONKEY; NONHUMAN; OVARIECTOMY; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029945376     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00157-6     Document Type: Article

References (53)

1. Alexander, G.M., Schwartzman, R.J., Grothusen, J.R., Brainard, L. and Gordon, S.W., Change in brain dopamine receptor in MPTP parkinsonian monkeys following L-Dopa treatment, Brain Res., 625 (1993) 276-282.
2. Anderson, P.H. and Jansen, J.A., Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy, Eur. J. Pharmacol., 188 (1990) 335-347.
3. Barbeau, A., High level levodopa therapy in several akinetic parkinsonian patients: twelve years later. In U.K. Rinne, M. Klinger and G. Stamm (Eds.), Parkinson's Disease: Current Progress, Problems and Managements, Elsevier, Amsterdam, 1980, pp. 229-239.
4. Barone, P., Davis, T.A., Braun, A.R. and Chase, T.N., Dopaminergic mechanisms and motor function: characterization of D1 and D2 dopamine receptor interactions, Eur. J. Pharmacol., 123 (1986) 109-113.
5. Baronti, F., Mouradian, M.M., Davis, T.L., Giuffra, M., Brughitta, G., Conant, K.E. and Chase, T.N., Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease, Ann. Neurol., 32 (1992) 776-781.
6. 3H-spiperone binding, Brain Res., 379 (1986) 294-299.
7. Bédard, P.J. and Boucher, R., Effect of D1 receptor stimulation in normal and MPTP monkeys, Neurosci. Lett., 104 (1989) 223-228.
8. Bédard, P.J., Gomez-Mancilla, B., Blanchette, P., Gagnon, C., Falardeau, P. and Di Paolo, T., Role of selective D1 and D2 agonists in inducing dyskinesia in drug naive MPTP monkeys, Adv. Neurol., 60 (1993) 113-118.
9. Blanchet, P., Bédard, P.J., Britton, D.R. and Kebabian, J.W., Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys, J. Pharmacol. Exp. Ther., 267 (1993) 275-279.
10. Blanchet, P.J., Grondin, R., Bédard, P.J., Shiosaki, K., Britton, D.R. and Kebabian, J.W., Differential regulation and behavioral effects of the mode of stimulation of dopamine D1 receptors in MPTP-exposed parkinsonian primates, Soc. Neuroscience, Vol. 20, 1994, pp. 1364.
11. Blanchet, P.J., Calon, F., Martel, J.C., Bédard, P.J., Di Paolo, T., Walters, R.R. and Piercey, M.F., Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys, J. Pharmacol. Exp. Ther., 272 (1995) 854-859.
12. Blanchet, P.J., Grondin, R. and Bédard, P.J., Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug naive MPTP-lesioned primates, Movement Dis., 11 (1996) 91-94.
13. Blanchette, P., Bédard, P.J., Matsumura, M., Richard, H. and Filion, M., Pathophysiology of levodopa-induced dyskinesia: changing concepts. In G. Percheron et al. (Eds.), The Basal Ganglia, Plenum Press, New York, 1994, pp. 539-548.
14. Boppana, V.K., Dolce, K.M., Cyronak, M.J. and Ziemniak, J.A., Simplified procedures for the determination of Fenoldopam and its metabolites in human plasma by high-performance liquid chromatography with electrochemical detection: comparison of manual and robotic sample preparation methods, J. Chromatogr., 487 (1989) 385-399.
15. Boyce, S.. Rupniak, N.M.J., Steventon, M.J. and Iversen, S.D., Differential effects of D1 or D2 agonist in MPTP treated primates: functional implication for Parkinson's disease, Neurology, 40 (1990) 927-933.
16. Braun, A., Mouradian, M.M., Mohr, E., Fabbrini, G. and Chase, T.N., Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders, J. Neurol. Neurosurg. Psych., 52 (1989) 631-635.
17. Britton, D.R., Kebabian, J.W. and Curzon, P., Rapid reversal of denervation supersensitivity of dopamine D1 receptors by L-dopa or a novel dopamine D1 receptor agonist, A68930, Eur. J. Pharmacol., 200 (1991) 89-93.
18. A receptors in the striatopallidal complex., Brain Res., 680 (1995) 43-52.
19. Darney, K.J., Lewis, M.H., Brewster, W.K., Nichols, D.E. and Mailman R.B., Behavioral effects in the rat of dihydrexidine, a high potency, full efficacy D1 dopamine receptor agonist, Neuropsychopharmacology, 5 (1991) 187-195.
20. Di Paolo, T., Bédard, P.J., Daigle, M. and Boucher, R., Long-term effects of MPTP on central and peripheral catecholamine and indolamine concentrations in monkeys, Brain Res., 379 (1986) 286-293.
21. Domino, E.F. and Sheng J., Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys, J. Pharmacol. Exp. The., 265 (1993) 1387-1391.
22. Falardeau, P., Bouchard, S., Bédard, P.J., Boucher, R. and Di Paolo, T., Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP-monkeys, Eur. J. Pharmacol., 150 (1988) 59-66.
23. Gagnon, C., Bédard P.J. and Di Paolo T., Effect of chronic treatment of MPTP monkeys with dopamine D1 and/or D2 receptor agonists, Eur. J. Pharmacol., 178 (1990) 115-120.
24. Gagnon, C., Gomez-Mancilla, B., Markstein, R., Bédard, P.J. and Di Paolo, T., Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors, Prog. Neuro. Psychopharmacol. Biol. Psychiat., 19 (1995) 667-676.
25. Gerfen, C.R., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, F.J., Jr. and Sibley, D.R., D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons, Science, 250 (1990) 1429-1432.
26. Gingrich, J.A. and Caron, M.G., Recent advances in the molecular biology of dopamine receptors, Annu. Rev. Neurosci., 16 (1993) 299-321.
27. Gomez-Mancilla, B., Boucher, R., Gagnon, C., Di Paolo, T., Markstein, R. and Bédard, P.J., Effect of adding the D1 agonist CY 208243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors, Movement Dis., 8 (1993) 144-150.
28. Graham, W.C., Sambrook, M.A. and Crossman, A.R., Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism, Brain Res., 620 (1993) 290-303.
29. Grondin, R., Blanchet, P.J., Bédard, P.J., Britton, D.R., Shiosaki, K. and Kebabian, J.W., Dramatic desensitization of the behavioral response to a long-acting D1 but not D2 agonist in MPTP monkeys, Soc. Neuroscience, Vol. 20, 1994, pp. 1645.
30. Izenwasser, S. and Katz, J.L., Differential efficacies of dopamine D1 receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat, Eur. J. Pharmacol. Mol. Pharmacol., 246 (1993) 39-44.
31. Kebabian, J.W. and Calne, D.B., Multiple receptors for dopamine, Nature, 277 (1979) 93-96.
32. Kebabian J.W., Britton D.R., DeNinno M.P., Perner R., Smith L., Jenner P., Schoenleber R. and Williams M., A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets, Eur. J. Pharmacol., 229 (1992) 203-209.
33. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J., Protein measurement with Folin phenol reagent, J. Biol. Chem., 193 (1951) 265-275.
34. Luquin M.R., Guillén J., Martínez-Vila E., Laguna J. and Martínez-Lage J.M., Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys, Eur. J. Pharmacol., 253 (1994) 215-224.
35. Markstein, R., Seiler, M.P., Vigouret, J.M., Urwyler, S., Enz, A. and Dixon, K., Pharmacological properties of CY 208-243, a novel D-1 agonist. In M. Sandler, A. Dahlstrom and R. Belkmaker (Eds.), Progress in Catecholamine Research, Part B, Alan R. Liss, New York, 1988, pp. 59-69.
36. Mottola D.M., Brewster W.K., Cook L.L., Nichols D.E. and Mailman R.B., Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist, J. Pharmacol. Exp. Ther., 262 (1992) 383-393.
37. Mouradian, M.M., Juncos, J.L., Fabbrini, G. and Chase, T.N., Motor fluctuations in Parkinson's disease: pathogenic and therapeutic studies, Ann. Neurol., 22 (1987) 475-479.
38. Mouradian, M.M., Heuser, I.J.E., Baronti, F. and Chase, T.N., Modifications of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease, Ann. Neurol., 27 (1990) 18-23.
39. Nutt, J.G., Levodopa induced dyskinesia: review, observations, and speculation, Neurology, 40 (1990) 340-345.
40. O'Boyle, K.M., Gaitanopoulos, D.E., Brenner, M. and Waddington J.L., Agonist and antagonist properties of benzazepine and thienopyridine derivatives at the D1 dopamine receptor, Neuropharmacology., 28 (1989) 401-405.
41. Parent, A. and Lavoie, B., The heterogeneity of the mesostriatal dopaminergic system as revealed in normal and parkinsonian monkeys. In H. Narabayashi, T. Nagatsu, N. Yanagisawa and Y. Mizuno (Eds.), Advances in Neurology, Vol. 60, Raven Press Ltd., New York, 1993, pp. 229-239.
42. Pérez-Otano, I., Oset, C., Luquin, M.R., Herrero, M.T., Obeso, J.A. and Del Rio, J., MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration, Neurosci. Lett., 175 (1994) 121-125.
43. Pifl, C., Reither, H. and Hornykiewicz, O., Lower efficacy of the dopamine D1 agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum, Eur. J. Pharmacol., 202 (1991) 273-276.
44. Rupniak, N.M.J., Boyce, S., Steventon, M. and Iversen, S.D., Weak antiparkinsonian activity of the D1 agonist C-APB (SKF 82958) and lack of synergism with a D2 agonist in primates, Clin. Neuropharmacol., 15 (1992) 307-309.
45. Seeman, P. and Van Tol, H.H.M., Dopamine receptor pharmacology, Trends Pharmacol. Sci., 15 (1994) 264-270.
46. Sibley, D.R. and Monsma, F.J. Jr., Molecular biology of dopamine receptors, Trends Pharmacol. Sci., 13 (1992) 61-68.
47. Silverman P.B., Sensitization, response fluctuation and long-term effect of SKF-82958 and bromocriptine in the hemi-parkinsonian rat, Eur. J. Pharmacol., 229 (1992) 235-240.
48. Subramaniam, S., Lucki, I. and McGonigle, P., Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors, Brain Res., 571 (1992) 313-322.
49. Taylor, J.R., Lawrence, M.S., Redmond, Jr. D.E., Elsworth, J.D., Roth, R.H., Nichols, D.E. and Mailman, R.B., Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys, Eur. J. Pharmacol., 199 (1991) 389-391.
50. Tsui, J.K.C., Wolters, E.C., Peppard, R.F. and Calne, D.B., A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease, Neurology, 39 (1989) 856-858.
51. Vermeulen, R.J., Drukarch, B., Sahadat, M.C.R., Goosen, C., Wolters, E.C. and Stoof, J.C., The selective dopamine D1 receptor agonist, SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeys, Eur. J. Pharmacol., 235 (1993) 143-147.
52. Walters, J.R., Bergstrom, D.A., Carlson, J.H., Chase, T.N. and Braun, A.R., D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects, Science, 236 (1987) 719-722.
53. Winkler, J.D. and Weiss, B., Effect of continuous exposure to selective D1 and D2 dopaminergic agonists on rotational behavior in supersensitive mice, J. Pharmacol. Exp. Ther., 249 (1989) 507-516.